Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scott, W. J.
Right arrow Articles by Movsas, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scott, W. J.
Right arrow Articles by Movsas, B.
(Chest. 2003;123:188S-201S.)
© 2003 American College of Chest Physicians

Treatment of Stage II Non-small Cell Lung Cancer*

Walter J. Scott, MD, FCCP; John Howington, MD, FCCP and Benjamin Movsas, MD

* From the Department of Surgical Oncology (Dr. Scott), Section of Thoracic Surgical Oncology; the Department of Radiation Oncology (Dr. Movsas), Fox Chase Cancer Center, Philadelphia, PA; and Department of Surgery (Dr. Howington), Division of Thoracic Surgery, University of Cincinnati Medical Center, Cincinnati, OH.

Correspondence to: Walter J. Scott, MD, FCCP, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111; e-mail: W_Scott{at}fccc.edu

Based on clinical assessment alone, patients with stage II non-small cell lung cancer (NSCLC) comprise only 5% of all patients with NSCLC. In addition, patients with stage II NSCLC represent a heterogeneous group, since stage II consists of patients with T1-2N1 or T3N0 tumors. By definition, patients with tumor invading the chest wall apex, mediastinum, diaphragm, or even the mainstem bronchus may all have T3 tumors. The extent of the data available regarding treatment of each of these different groups is therefore limited. The quality of the data is limited as well, because information often comes from small series of patients. Studies of adjuvant therapy after complete resection of stage II NSCLC are an important exception to this generalization, since data from large, randomized studies of adjuvant radiation therapy, chemotherapy, or a combination of the two are available for analysis. Superior sulcus tumors are discussed elsewhere in these guidelines.

Key Words: carcinoma • bronchogenic • chemotherapy • guidelines • lung • neoplasms • neoplasm • staging • practice guidelines • radiotherapy • surgery






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.